We are live on ! Find out more
TSC

Two Seas Capital Portfolio holdings

AUM $8.68B
1-Year Est. Return 78.08%
This Fund
S&P 500
This Quarter Est. Return
+5.9%
1 Year Est. Return
+78.08%
3 Year Est. Return
+344.2%
5 Year Est. Return
+575.95%
10 Year Est. Return
–
AUM
$617M
AUM Growth
+$1.97M
Cap. Flow
-$797K
Cap. Flow %
-0.13%
Top 10 Hldgs %
87.84%
Holding
28
New
8
Increased
6
Reduced
10
Closed
2
Avg Time Held Equity + Options
3.2 quarters
Top 10 Avg Time Held Equity + Options
4.3 quarters
Top 20 Avg Time Held Equity + Options
3.4 quarters
Avg Time Held Equity only
3.4 quarters
Top 10 Avg Time Held Equity only
4.3 quarters
Top 20 Avg Time Held Equity only
3.4 quarters

Top Buys

Rank Stock Value
1
TLN icon
Talen Energy Corp
TLN
+$63.3M
2
EXEL icon
Exelixis
EXEL
+$11.3M
3
CLMT icon
Calumet Specialty Products
CLMT
+$4.97M
4
CEG icon
Constellation Energy
CEG
+$4.97M
5
INDV icon
Indivior Pharmaceuticals
INDV
+$4.68M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$6.76M
2
CORZ icon
Core Scientific
CORZ
+$5.53M
3
VST icon
Vistra
VST
+$5.21M
4
ARQT icon
Arcutis Biotherapeutics
ARQT
+$4.44M
5
OMEX icon
Odyssey Marine Exploration
OMEX
+$3.94M

Sector Composition

Rank Sector Weight
1 Healthcare 57.12%
2 Utilities 18.87%
3 Technology 12.02%
4 Miscellaneous 5.33%
5 Communication Services 4.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
INDV icon
1
Indivior Pharmaceuticals
INDV
$4.26B
$127M 20.58%
13,030,027
+400,001
+3% +$4.68M
2023 Q2
5 quarters
ROIV icon
2
Roivant Sciences
ROIV
$25B
$112M 18.18%
9,724,893
-593,871
-6% -$6.76M
2021 Q4
11 quarters
TLN icon
3
Talen Energy Corp
TLN
$18B
$80.1M 12.97%
+449,115
New +$63.3M
2024 Q3
0 quarters
CORZ icon
4
Core Scientific
CORZ
$4.83B
$67.7M 10.96%
5,705,791
-533,800
-9% -$5.53M
2024 Q1
2 quarters
ABUS icon
5
Arbutus Biopharma
ABUS
$822M
$32.3M 5.23%
8,387,388
-184,363
-2% -$707K
2021 Q4
11 quarters
VST icon
6
Vistra
VST
$53.1B
$30M 4.85%
252,666
-61,416
-20% -$5.21M
2024 Q1
2 quarters
AVDL
7
DELISTED
Avadel Pharmaceuticals
AVDL
$29.6M 4.79%
2,253,780
+138,501
+7% +$2.11M
2024 Q1
2 quarters
EXEL icon
8
CALL
Exelixis
EXEL
$14.8B
$23.6M 3.82%
907,900
+796,600
+716% +$19.8M
2024 Q2
1 quarter
META icon
9
Meta Platforms (Facebook)
META
$1.89T
$20.6M 3.33%
35,958
+5,000
+16% +$2.57M
2022 Q4
7 quarters
IMVT icon
10
Immunovant
IMVT
$6.09B
$19.3M 3.13%
676,614
-15,792
-2% -$466K
2023 Q3
4 quarters
EXEL icon
11
Exelixis
EXEL
$14.8B
$11.8M 1.9%
+453,103
New +$11.3M
2024 Q3
0 quarters
ESPR icon
12
DELISTED
Esperion Therapeutics
ESPR
$10.9M 1.76%
6,584,278
+848,618
+15% +$1.71M
2023 Q2
5 quarters
SHC icon
13
Sotera Health
SHC
$5.18B
$6.68M 1.08%
400,000
+50,000
+14% +$730K
2024 Q1
2 quarters
GOOGL icon
14
Alphabet (Google) Class A
GOOGL
$4.31T
$6.63M 1.07%
40,000
-9,371
-19% -$1.57M
2024 Q1
2 quarters
SONO icon
15
Sonos
SONO
$2.05B
$6.5M 1.05%
528,928
-175,000
-25% -$2.22M
2022 Q3
8 quarters
CEG icon
16
Constellation Energy
CEG
$104B
$6.5M 1.05%
+25,000
New +$4.97M
2024 Q3
0 quarters
CLMT icon
17
Calumet Specialty Products
CLMT
$5.03B
$5.52M 0.89%
+310,007
New +$4.97M
2024 Q3
0 quarters
ARQT icon
18
Arcutis Biotherapeutics
ARQT
$3.3B
$2.9M 0.47%
312,122
-450,068
-59% -$4.44M
2024 Q1
2 quarters
HUT icon
19
Hut 8
HUT
$10.5B
$2.51M 0.41%
+204,916
New +$2.72M
2024 Q3
0 quarters
PCRX icon
20
PUT
Pacira BioSciences
PCRX
$1.45B
$2.38M 0.39%
+158,400
New +$2.71M
2024 Q3
0 quarters
IREN icon
21
Iris Energy
IREN
$13.7B
$2.32M 0.38%
+275,000
New +$2.53M
2024 Q3
0 quarters
WULF icon
22
TeraWulf
WULF
$6.67B
$2.02M 0.33%
432,626
-67,374
-13% -$306K
2024 Q2
1 quarter
CORZW icon
23
Core Scientific Inc Tranche 1 Warrants
CORZW
$818M
$1.89M 0.31%
280,248
– –
2024 Q1
2 quarters
BTBT icon
24
Bit Digital
BTBT
$447M
$1.45M 0.23%
+412,414
New +$1.37M
2024 Q3
0 quarters
OMEX icon
25
Odyssey Marine Exploration
OMEX
$37.6M
$82.8K 0.01%
100,000
-1,050,666
-91% -$3.94M
2021 Q4
11 quarters
1
2

Similar funds

PGFC
Peapack-Gladstone Financial Corp Bedminster, New Jersey $8.7B AUM 29.75% 1-Year Est. Return
GA
Greenhaven Associates Purchase, New York $8.66B AUM 17.37% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.7B AUM 37.59% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
SP
Sarasin & Partners London, United Kingdom $8.54B AUM 9.6% 1-Year Est. Return
MT
Midwest Trust Overland Park, Kansas $8.83B AUM 27.45% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

Two Seas Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Two Seas Capital held 28 positions worth $617M, up 0.32% from $615M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Two Seas Capital's Q3 2024 filing shows 8 new, 6 increased, 10 reduced and 2 closed positions. Its largest new stake was Talen Energy Corp: 449,115 shares worth $80.1M. The largest sale was Roivant Sciences, an estimated $6.76M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 67% a quarter earlier, followed by Utilities and Technology.

  • Two Seas Capital's largest Q3 2024 buy was Talen Energy Corp: 449,115 shares worth $80.1M.
  • Two Seas Capital added most to Indivior Pharmaceuticals in Q3 2024, an estimated $4.68M increase.
  • Two Seas Capital's biggest Q3 2024 reduction was Roivant Sciences, cutting an estimated $6.76M.
  • Two Seas Capital fully exited Core Scientific Inc Tranche 2 Warrants in Q3 2024, selling an estimated $2.02M.
  • Two Seas Capital's ten largest holdings make up 88% of its $617M portfolio in Q3 2024.
  • Two Seas Capital opened 8 new positions and closed 2 in Q3 2024.
  • Two Seas Capital's portfolio value rose 0.32% quarter-over-quarter to $617M.

Based on Two Seas Capital's 13F filing for Q3 2024, filed 14 Nov 2024.